Skip to main content
SpringerLink
Log in

Telitacicept: First Approval

  • AdisInsight Report
  • Published:
Drugs Aims and scope Submit manuscript

This article has been updated

Abstract

Telitacicept (Tai'ai®) is fusion protein comprising a recombinant transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI) receptor fused to the fragment crystallizable (Fc) domain of human immunoglobulin G (IgG). Telitacicept is being developed by Yantai Rongchang Pharmaceutical through its subsidiary RemeGen for the treatment of B cell-mediated autoimmune diseases, such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA) and multiple sclerosis (MS). Telitacicept binds to and neutralizes the activity of two cell-signalling molecules, B-lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL), thereby suppressing the development and survival of plasma cells and mature B cells. In March 2021, telitacicept received its first approval in China for the treatment of patients with active SLE. Clinical studies of telitacicept in several other indications, including IgA nephropathy, MS, myasthenia gravis, neuromyelitis optica spectrum disorders, RA and Sjögren's syndrome are underway in China. This article summarizes the milestones in the development of telitacicept leading to this first approval for SLE.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Change history

  • 13 September 2021

    Format errors

References

  1. Liossis SN, Staveri C. What’s new in the treatment of systemic lupus erythematosus. Front Med. 2021;8:221.

    Article  Google Scholar 

  2. Karrar S, Cunninghame Graham DS. Abnormal B cell development in systemic lupus erythematosus: what the genetics tell us. Arthritis Rheumatol. 2018;70(4):496–507.

    Article  Google Scholar 

  3. Choi J, Kim ST, Craft J. The pathogenesis of systemic lupus erythematosus: an update. Curr Opin Immunol. 2012;24(6):651–7.

    Article  CAS  Google Scholar 

  4. Pan L, Lu MP, Wang JH, et al. Immunological pathogenesis and treatment of systemic lupus erythematosus. World J Pediatr. 2020;16(1):19–30.

    Article  Google Scholar 

  5. Fan Y, Hao YJ, Zhang ZL. Systemic lupus erythematosus: year in review 2019. Chin Med J (Engl). 2020;133(18):2189–96.

    Article  Google Scholar 

  6. Bag-Ozbek A, Hui-Yuen JS. Emerging B-cell therapies in systemic lupus erythematosus. Ther Clin Risk Manag. 2021;17:39–54.

    Article  Google Scholar 

  7. Yao X, Ren Y, Zhao Q, et al. Pharmacokinetics analysis based on target-mediated drug distribution for RC18, a novel BLyS/APRIL fusion protein to treat systemic lupus erythematosus and rheumatoid arthritis. Eur J Pharm Sci. 2021;159:105704.

    Article  CAS  Google Scholar 

  8. Zhao Q, Chen X, Hou Y, et al. Pharmacokinetics, pharmacodynamics, safety, and clinical activity of multiple doses of RCT-18 in Chinese patients with systemic lupus erythematosus. J Clin Pharmacol. 2016;56(8):948–59.

    Article  CAS  Google Scholar 

  9. Remegen. Telitacicept: NMPA approval on 9th March. 2021. http://www.remegen.com/Project.aspx?ClassID=21#ttxp. Accessed 28 Jun 2021.

  10. Remegen. Telitacicept: Chinese prescribing information. Yantai: Rongchang Biopharmaceutical (Yantai) Co., Ltd; 2021.

    Google Scholar 

  11. Yung S, Yap DY, Chan TM. A review of advances in the understanding of lupus nephritis pathogenesis as a basis for emerging therapies. F1000Res. 2020. https://doi.org/10.12688/f1000research.22438.1.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Chen X, Zhao Q, Hou Y, et al. Pharmacokinetics, pharmacodynamics, short term efficacy and safety of RCT-18, a novel BLyS/APRIL fusion protein, in patients with rheumatoid arthritis. Br J Clin Pharmacol. 2016;82(1):41–52.

    Article  CAS  Google Scholar 

  13. Wu D, Li J, Xu D, et al. A human recombinant fusion protein targeting B lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (April), telitacicept (RC18), in systemic lupus erythematosus (SLE): results of a phase 2b study [abstract no. L18]. Arthritis Rheumatol. 2019;71(Suppl 10):5262–4.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand

    Sohita Dhillon

Authors
  1. Sohita Dhillon
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sohita Dhillon.

Ethics declarations

Funding

The preparation of this review was not supported by any external funding.

Authorship and conflict of interest

During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Sohita Dhillon is a contracted employee of Adis International Ltd/Springer Nature and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.

Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability

Not applicable.

Additional information

This profile has been extracted and modified from the AdisInsight database. AdisInsight tracks drug development worldwide through the entire development process, from discovery, through pre-clinical and clinical studies to market launch and beyond.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (PPTX 504 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Dhillon, S. Telitacicept: First Approval. Drugs 81, 1671–1675 (2021). https://doi.org/10.1007/s40265-021-01591-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40265-021-01591-1

Search

Navigation